Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tegafur + gimeracil + oteracil (Taiho Pharmaceutical Co., Ltd.)
- Development stage
- Unknown
- Lead developer
- Taiho Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
S-1 is an oral fluoropyrimidine combination chemotherapy agent composed of tegafur, gimeracil, and oteracil potassium in a molar ratio of 1:0.4:1. Tegafur is a prodrug that is converted into 5-fluorouracil (5-FU) in the body. Gimeracil (5-chloro-2,4-dihydroxypyridine) is a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), the enzyme responsible for 5-FU degradation, thereby maintaining high plasma concentrations of 5-FU. Oteracil potassium (monopotassium 1,2,4-triazine-3,5-dione-6-carboxylate) selectively inhibits the phosphorylation of 5-FU by orotate phosphoribosyltransferase (OPRT) in the gastrointestinal tract, which reduces the gastrointestinal toxicity associated with 5-FU. Originally developed by Taiho Pharmaceutical, S-1 is primarily used for the treatment of various solid tumors, including gastric, colorectal, and esophageal cancers. In clinical research, it is often studied as a component of concurrent chemoradiotherapy regimens.
- Brand names
- TS-1TS1TS 1Teysuno
- Other names
- Tegafur/Gimeracil/Oteracil
02
Targets
TS (Thymidylate synthase)OPRT (Orotidine 5'-phosphate decarboxylase)DPYD (Dihydropyrimidine dehydrogenase)
Beyond the preview
Go deeper on tegafur + gimeracil + oteracil (Taiho Pharmaceutical Co., Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tegafur + gimeracil + oteracil (Taiho Pharmaceutical Co., Ltd.).